Regulatory T Cells in the Tumor Microenvironment

被引:19
作者
Dadey, Rebekah E. [1 ,2 ,3 ,4 ]
Workman, Creg J. [1 ,2 ,3 ]
Vignali, Dario A. A. [1 ,2 ,3 ]
机构
[1] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh Med Ctr UPMC, Hillman Canc Ctr, Tumor Microenvironm Ctr, Pittsburgh, PA 15213 USA
[3] UPMC Hillman Canc Ctr, Canc Immunol & Immunotherapy Program, Pittsburgh, PA 15213 USA
[4] Univ Pittsburgh, Sch Med, Grad Program Microbiol & Immunol, Pittsburgh, PA USA
来源
TUMOR MICROENVIRONMENT: HEMATOPOIETIC CELLS, PT B | 2020年 / 1273卷
关键词
Regulatory T cells (T-reg); Tumor immunology; Tolerance; Tumor microenvironment (TME); Foxp3; CD25; IL-2; CTLA4; NRP1; LAG3; CD39; IL-10; IL-35; Cancer immunotherapy; Clinical trials; MEDIATED ANTITUMOR IMMUNITY; VERSUS-HOST-DISEASE; GROWTH-FACTOR-BETA; CUTTING EDGE; FOXP3; EXPRESSION; TRYPTOPHAN CATABOLISM; MONOCLONAL-ANTIBODY; PD-1; BLOCKADE; GRANZYME-B; TREG CELLS;
D O I
10.1007/978-3-030-49270-0_6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Regulatory T cells (T-regs) are an immunosuppressive subpopulation of CD4+ T cells that are endowed with potent suppressive activity and function to limit immune activation and maintain homeostasis. These cells are identified by the hallmark transcription factor FOXP3 and the high-affinity interleukin-2 (IL-2) receptor chain CD25. T-regs can be recruited to and persist within the tumor microenvironment (TME), acting as a potent barrier to effective antitumor immunity. This chapter will discuss [i] the history and hallmarks of T-regs; [ii] the recruitment, development, and persistence of T-regs within the TME; [iii] T-reg function within TME; asnd [iv] the therapeutic targeting of T-regs in the clinic. This chapter will conclude with a discussion of likely trends and future directions.
引用
收藏
页码:105 / 134
页数:30
相关论文
共 319 条
  • [1] Regulatory T cells: recommendations to simplify the nomenclature
    Abbas, Abul K.
    Benoist, Christophe
    Bluestone, Jeffrey A.
    Campbell, Daniel J.
    Ghosh, Sankar
    Hori, Shohei
    Jiang, Shuiping
    Kuchroo, Vijay K.
    Mathis, Diane
    Roncarolo, Maria Grazia
    Rudensky, Alexander
    Sakaguchi, Shimon
    Shevach, Ethan M.
    Vignali, Dario A. A.
    Ziegler, Steve F.
    [J]. NATURE IMMUNOLOGY, 2013, 14 (04) : 307 - 308
  • [2] Natural and induced T regulatory cells in cancer
    Adeegbe, Dennis O.
    Nishikawa, Hiroyoshi
    [J]. FRONTIERS IN IMMUNOLOGY, 2013, 4
  • [3] Tumor-infiltrating human CD4+ regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity
    Ahmadzadeh, Mojgan
    Pasetto, Anna
    Jia, Li
    Deniger, Drew C.
    Stevanovic, Sanja
    Robbins, Paul F.
    Rosenberg, Steven A.
    [J]. SCIENCE IMMUNOLOGY, 2019, 4 (31)
  • [4] Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells
    Ai, Weiyun Z.
    Hou, Ling-Zhou
    Zeiser, Robert
    Czerwinski, Debra
    Negrin, Robert S.
    Levy, Ronald
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (01) : 239 - 244
  • [5] Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer
    Aida, Kouichirou
    Miyakawa, Reina
    Suzuki, Koji
    Narumi, Kenta
    Udagawa, Takeshi
    Yamamoto, Yuki
    Chikaraishi, Tatsuya
    Yoshida, Teruhiko
    Aoki, Kazunori
    [J]. CANCER SCIENCE, 2014, 105 (02) : 159 - 167
  • [6] Human lung tumor FOXP+ Tregs upregulate four "Treg-locking" transcription factors
    Akimova, Tatiana
    Zhang, Tianyi
    Negorev, Dmitri
    Singhal, Sunil
    Stadanlick, Jason
    Rao, Abhishek
    Annunziata, Michael
    Levine, Matthew H.
    Beier, Ulf H.
    Diamond, Joshua M.
    Christie, Jason D.
    Albelda, Steven M.
    Eruslanov, Evgeniy B.
    Hancock, Wayne W.
    [J]. JCI INSIGHT, 2017, 2 (16):
  • [7] Helios Expression Is a Marker of T Cell Activation and Proliferation
    Akimova, Tatiana
    Beier, Ulf H.
    Wang, Liqing
    Levine, Matthew H.
    Hancock, Wayne W.
    [J]. PLOS ONE, 2011, 6 (08):
  • [8] The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
    Allard, Bertrand
    Longhi, Maria Serena
    Robson, Simon C.
    Stagg, John
    [J]. IMMUNOLOGICAL REVIEWS, 2017, 276 (01) : 121 - 144
  • [9] Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions
    Amedei, Amedeo
    Niccolai, Elena
    Benagiano, Marisa
    Della Bella, Chiara
    Cianchi, Fabio
    Bechi, Paolo
    Taddei, Antonio
    Bencini, Lapo
    Farsi, Marco
    Cappello, Paola
    Prisco, Domenico
    Novelli, Francesco
    D'Elios, Mario Milco
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (07) : 1249 - 1260
  • [10] Preclinical characterization of AB154, a fully humanized anti-TIGIT antibody, for use in combination therapies
    Anderson, Amy E.
    Becker, Annette
    Yin, FangFang
    Singh, Hema
    Zhao, Xiaoning
    Seitz, Lisa
    Stanton, Rick
    Walker, Nigel P. C.
    Tan, Joanne B. L.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)